Tempest Therapeutics is a biopharmaceutical company, focused on developing treatments for endocrine diseases. Co.'s three product candidates are: Livoletide (AZP-531), which is for the treatment Prader-Willi syndrome, a genetic endocrine disease usually characterized by hyperphagia, or insatiable hunger; nevanimibe (ATR-101), which is a potential treatment for patients with congenital adrenal hyperplasia, a monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses; and NK3R antagonist (MLE-301), which is a potential treatment of vasomotor symptoms commonly known as hot flashes and night sweats, in menopausal women. The TPST YTD return is shown above.
The YTD Return on the TPST YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether TPST YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TPST YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|